Business
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n LAS VEGAS, March 29, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired, biopharmaceutical research and development company, announces that their sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was published in the International Journal of Pharmaceutics on March 25. For the Gb Sciences-sponsored study, researchers at the University of Seville in Spain have developed time-released, oral nanoparticles to deliver Gb Sciences' patent-protected chronic pain formulations, which are based on synergistic mixtures of terpenes. Terpenes are normally highly volatile, highly lipophilic molecules that are difficult to formulate into stable drug products, so Gb Sciences and their colleagues believe that nanocarriers can improve their stability, solubility, and bioavailability. \"This research represents an important advance in the creation of novel terpene-containing pharmaceutical products for chronic pain, which have the potential to deliver relief over time in a safer and more efficient manner through our time-released delivery technology,\" said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences, who co-authored the paper with researchers from the University of Seville in Spain and Chaminade University in Hawai'i. \"There was a considerable technological challenge to developing a suitable drug delivery system for terpenes. This study demonstrates how nanomedicines offer an elegant solution for administering these efficacious molecules and opens up new opportunities for their use in chronic pain medicines.\" In the U.S. alone, chronic pain represents an estimated health burden of between $560 and $650 billion dollars, and an estimated 20.4% of U.S. adults suffer from chronic pain that significantly decreases their quality of life. Despite the widespread rates of addiction and death, opioids remain the standard of care treatment for most people with chronic pain. Concerns over those issues have made novel chronic pain treatments such as Gb Sciences' therapies an important and promising field of research and development. The Gb Sciences-sponsored study tested the effect of poly(lactide-co-glycolide) nanoparticles containing the three terpenes v...